OR-CCIX-CONSORTIUM
The CCIX Consortium (CCIX) and Green Computing Consortium (GCC) announced today that they have signed a Memorandum of Understanding (MoU) to collaborate on endorsing CCIX as a unified industry standard interconnect technology and an essential requirement in the GCC server standards reference guide. Through this partnership, GCC and CCIX will jointly promote the awareness and the adoption of CCIX technology in the server ecosystem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190409005046/en/
With the execution of this MoU, CCIX and GCC have agreed to complement the GCC green computing standards framework with CCIX as one of the pillar technologies to further the ecosystem of green computing. The long-term goals of this collaboration are centered on advancing high-performance, low-power green computing with heterogeneous cache coherent acceleration architectures.
The CCIX Consortium was founded to develop and promote the adoption of an industry standard specification to enable coherent interconnect technologies between general-purpose processors and acceleration devices for efficient heterogeneous computing. Heterogeneous compute architectures leverage accelerators to complete today’s compute tasks faster and with lower power consumption than the processor working on its own. CCIX’s non-proprietary standard enables vendors of processors, accelerators and other peripheral devices to simplify how heterogeneous systems are architected, establishing a seamless chip-to-chip communication and take advantage of the additional bandwidth, reduced latency and lower power consumption opportunities that CCIX provides.
“The CCIX Consortium is honored to collaborate with the Green Computing Consortium in the promotion of the CCIX Standard among the GCC membership,” said Gaurav Singh, Chairman, CCIX Consortium. “This collaboration is further validation of our leadership in coherent interconnect technologies and will enable servers based on the GCC specifications to provide outstanding performance.”
The Green Computing Consortium is dedicated to the ecosystem development and market promotion of green computing products based on the Arm computing chipsets technology. GCC works on the standardization, test and certification, system enablement, pilot programs, open source projects, and education and training of young professionals. As a state-of-the-art architecture and standards overview, GCC released in 2018 the“Green Computing Consortium Server Technical Standards Report.”
“GCC believes that the CCIX specification provides key technology for heterogeneous acceleration that enables the consortium members to deliver green computing servers with unprecedented power efficiency and price/performance that meets the next generation cloud and datacenter requirements,” said Hong Mei, General Director, GCC. “We believe the CCIX Consortium is a leader in providing coherent interconnect technologies and greatly value this strategic partnership.”
About CCIX Consortium, Inc.
CCIX Consortium was founded to enable a new class of interconnect focused on emerging acceleration applications such as machine learning, network processing, storage off-load, in-memory database and 4G/5G wireless technology. The standard allows processors based on different instruction set architectures to extend the benefits of cache coherent, peer processing to acceleration devices including FPGAs, GPUs, network/storage adapters, intelligent networks, and custom ASICs, allowing system designers to seamlessly integrate the right combination of heterogeneous components for their specific system needs. For more information, please visit www.ccixconsortium.com .
About Green Computing Consortium
Green Computing Consortium is organized, on a voluntary, equitable, mutually beneficial and cooperative basis, by all interested parties of the industry, including but not limited to technology provider, manufacturer, system integrators and business users. The mission of the Consortium is following the technology trends of open source software and open hardware, gathering strength of all interested parties in the industry chain, and providing end business users with easier use and management green energy-saving products based on the Arm computing chipsets technology. For more information, please visit www.opengcc.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190409005046/en/
Contact:
CCIX Consortium: Matthew Baxter, Nereus mbaxter@nereus-worldwide.com +1.503.619.2676
Green Computing Consortium: Mr. Li Weizhong liwz@itssmedia.cn
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom